ERK 3 Inhibitors
ERK 3 inhibitors belong to a specific chemical class of compounds that target the enzyme known as Extracellular Signal-Regulated Kinase 3 (ERK3). ERK3 is a member of the mitogen-activated protein kinase (MAPK) family, which plays a crucial role in cellular signal transduction and regulation of various cellular processes. The inhibitors designed to selectively target ERK3 are small molecules that interact with the enzyme's active site, impeding its catalytic function. By disrupting ERK3's activity, these inhibitors can modulate the signaling pathways in which ERK3 is involved.
ERK3 inhibitors are designed with precision to exert a specific inhibitory effect on this particular kinase without significantly affecting other kinases or related pathways. The inhibition of ERK3 can lead to altered cellular responses, potentially affecting processes such as cell proliferation, differentiation, apoptosis, and cellular stress responses. Researchers and drug developers are interested in studying these inhibitors to better understand the biological functions of ERK3 and its involvement in various cellular events. The discovery and development of ERK3 inhibitors are driven by the desire to expand our knowledge of cellular signaling mechanisms and identify potential targets for various conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 869766 | 923032-37-5 | sc-364427 sc-364427A | 5 mg 10 mg | $245.00 $428.00 | 1 | |
BAY 869766 is an ERK3 inhibitor that selectively binds to the kinase domain of ERK3, leading to inhibition of its kinase activity. This selective targeting disrupts ERK3's role in mediating cellular proliferation and differentiation processes. | ||||||
CCT 137690 | 1095382-05-0 | sc-362722 sc-362722A | 10 mg 50 mg | $225.00 $945.00 | ||
CCT 137690 is an ATP-competitive inhibitor of ERK3, designed by researchers from the Structural Genomics Consortium (SGC). By competing with ATP for binding to ERK3, it effectively inhibits the kinase's activity, providing insights into ERK3's cellular functions through selective inhibition. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
LY3214996 selectively inhibits ERK3 by interfering with its kinase activity. This selective inhibition allows for the study of ERK3's contributions to cellular signaling pathways, enhancing understanding of its regulatory functions. | ||||||
XMD 8-92 (free base) | 1234480-50-2 | sc-364068 sc-364068A sc-364068B sc-364068C | 5 mg 10 mg 100 mg 1 g | $235.00 $340.00 $1700.00 $10330.00 | 10 | |
XMD8-92 is a potent inhibitor that selectively targets ERK3, inhibiting its activity and facilitating research into ERK3's role in cellular functions and signaling pathways. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
Although primarily targeting ERK1/2, SCH772984 also inhibits ERK3, offering a unique opportunity to study the function of ERK3 and its overlap with ERK1/2 signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
While known as a multikinase inhibitor, Sorafenib's ability to inhibit ERK3 in particular contexts allows for the exploration of ERK3's activities and its implications in cellular signaling mechanisms. | ||||||